Price
Financials
Standalone, Rs crore| Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Operating Profit | -0.01 | 0.00 | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| OPM % | ||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.01 | 0.00 | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Net Profit | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 |
| EPS in Rs | -0.02 | 0.00 | -0.02 | -0.02 | 0.00 | -0.02 | -0.02 | 0.00 |
| Jun 2006 15m | Mar 2007 9m | Mar 2008 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 13.84 | 0.63 | 1.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 12.56 | 6.92 | 2.39 | 0.20 | 0.04 | 0.02 | 0.03 | 0.02 |
| Operating Profit | 1.28 | -6.29 | -1.34 | -0.20 | -0.04 | -0.02 | -0.03 | -0.02 |
| OPM % | 9.25% | -998.41% | -127.62% | |||||
| Other Income | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 2.03 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.28 | 0.13 | 0.06 | 0.04 | 0.02 | 0.02 | 0.02 | 0.00 |
| Profit before tax | -1.03 | -6.67 | -1.39 | -0.24 | -0.06 | -0.04 | -0.05 | -0.02 |
| Tax % | -5.83% | 0.15% | 0.00% | 4.17% | 0.00% | 0.00% | 0.00% | |
| Net Profit | -0.97 | -6.68 | -1.39 | -0.25 | -0.06 | -0.04 | -0.04 | -0.02 |
| EPS in Rs | -1.94 | -13.39 | -2.79 | -0.50 | -0.12 | -0.08 | -0.08 | -0.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | % | ||
| Compounded Profit Growth | % | 15% | 23% | 33% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | % | % | % |
| Jun 2006 | Mar 2007 | Mar 2008 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 |
| Reserves | 1.40 | -5.28 | -6.67 | -7.38 | -7.44 | -7.48 | -7.53 |
| Borrowings | 15.63 | 16.20 | 16.19 | 16.19 | 16.19 | 19.20 | 19.22 |
| Other Liabilities | 7.66 | 4.48 | 4.67 | 4.47 | 4.39 | 1.42 | 1.31 |
| Total Liabilities | 29.68 | 20.39 | 19.18 | 18.27 | 18.13 | 18.13 | 17.99 |
| Fixed Assets | 1.21 | 1.08 | 1.00 | 0.92 | 0.89 | 0.87 | 0.85 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 28.47 | 19.31 | 18.18 | 17.35 | 17.24 | 17.26 | 17.14 |
| Total Assets | 29.68 | 20.39 | 19.18 | 18.27 | 18.13 | 18.13 | 17.99 |
| Jun 2006 | Mar 2007 | Mar 2008 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0.00 | 0.00 | -0.01 | 0.00 | |||
| Cash from Investing Activity | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Cash from Financing Activity | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Net Cash Flow | 0.00 | 0.00 | -0.01 | 0.00 | |||
| Free Cash Flow | 0.00 | 0.00 | -0.01 | 0.00 | |||
| CFO/OP | 0% | 0% | 50% | 0% |
| Jun 2006 | Mar 2007 | Mar 2008 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 482.89 | 8,632.54 | 4,599.00 | ||||
| Inventory Days | 181.06 | 394.02 | 890.44 | ||||
| Days Payable | 182.29 | 652.11 | 1,776.87 | ||||
| Cash Conversion Cycle | 481.65 | 8,374.44 | 3,712.57 | ||||
| Working Capital Days | 539.59 | 8,487.70 | 4,672.00 | ||||
| ROCE % | -9.14% | -0.44% | -0.26% | -0.30% |
Fundamentals
Market Cap₹ Cr.
Current Price₹ 3.40
Book Value₹ 10.0
ROCE-0.30 %
ROE%
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)%
Compounded Profit Growth (TTM)33%
Standalone figures.
Valuation
P/B, 3-year average-6.96x
Profitability
ROE12.29%
ROCE-1.70%
ROA-1.34%
ROE, 3-year average-21.87%
ROCE, 3-year average-14.90%
ROA, 3-year average-11.68%
ROIC (approx.)-1.81%
Tax rate-4.17%
Per share
EPS (TTM)Rs -0.08
EPS (latest year)Rs -0.50
EPS (latest quarter)Rs -0.02
EPS, 3-year averageRs -5.56
Book value per shareRs -4.79
Free cash flow per shareRs 0.00
Efficiency
Inventory turnover0.00x
Creditor days1777 days
Cash conversion cycle3713 days
Working capital days4672 days
Leverage
Total debtRs 16 Cr
Cash and bankRs 0 Cr
Net debtRs 16 Cr
Debt to equity-6.77x
Owners' fund to total sources-13.08%
Debt to assets88.62%
Cash flow
Free cash flow (latest year)Rs 0 Cr
FCFE (approx.: FCF + change in debt)Rs 0 Cr
Statement figures
Operating profit (latest quarter)Rs -0 Cr
EBITDA (TTM)Rs -0 Cr
PBDT (TTM)Rs -0 Cr
Profit before tax (TTM)Rs -0 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs -0 Cr
Net profit (latest year)Rs -0 Cr
Net profit (latest quarter)Rs -0 Cr
Depreciation (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 0 Cr
Total income (latest year)Rs 0 Cr
Share capitalRs 5 Cr
ReservesRs -7 Cr
Shareholders' fundsRs -2 Cr
Total assetsRs 18 Cr
Net blockRs 1 Cr
ReceivablesRs 13 Cr
InventoryRs 2 Cr
Other liabilitiesRs 4 Cr
Shares outstanding (crore)0.50
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
| serious | Negative equity Shareholders' equity is negative |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Dec 2014Sales ₹0 Cr.
Net profit ₹0 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Venkat Pharma Ltd?
Venkat Pharma Ltd (532093) has a market capitalisation of Rs Cr. at the close.
What were Venkat Pharma Ltd's latest quarterly results?
In the Dec 2014 quarter, Venkat Pharma Ltd sales was Rs 0 Cr and net profit was Rs 0 Cr.